Orchid Withdraws $126M Stock Offering | GenomeWeb

NEW YORK, Oct. 16 - Orchid Biosciences has withdrawn a proposed follow-on public offering of over 21/2 million shares of new stock, the Princeton, N.J. company announced Monday.

The manufacturer of SNP scoring technology filed the follow-on public offering with the Securities and Exchange Commission September 22. The total offering was valued at $126,143,500, according to the filing, and included a total of 4,025,000 shares of common stock: the 2 1/2 million new shares, one million existing shares, and additional " green shoe" shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.